SLC35D3 (Gene)

Organism:

Homo sapiens

Synonyms:ENTREZ:340146, FRCL1, HGNC:15621, MIM:612519, NM_001008783, NP_001008783, SLC35D3, solute carrier family 35 member D3

Id:ENSG00000182747

Entrez:340146

Ensembl:ENSG00000182747

Description:solute carrier family 35 member D3

Predicted to enable antiporter activity and pyrimidine nucleotide-sugar transmembrane transporter activity. Predicted to be involved in carbohydrate transport and pyrimidine nucleotide-sugar transmembrane transport. Predicted to act upstream of or within energy homeostasis and positive regulation of protein exit from endoplasmic reticulum. Predicted to be located in early endosome and endoplasmic reticulum. Predicted to be integral component of membrane. Predicted to be active in Golgi apparatus. [provided by Alliance of Genome Resources, Apr 2022]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View SLC35D3's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with SLC35D3.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using SLC35D3.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for SLC35D3.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with SLC35D3.

Results found

Linked to

	Label	Description
	GSE203362 0 V 1 ENZALUTAMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE193351 ruxolitinib 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216273 GSE216292 palbociclib 14 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE173116 GSE173118 ML-7 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216273,GSE216292 14 V 1 PALBOCICLIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE173483 nutlin-3 U2OS 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE172458 0 V 1 CISPLATIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE155031 5 V 3 DEXTRAN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE193177 1 V 0 ST266 MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE217441,GSE217443 1 V 0 IVOSIDENIB MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS

GSE203362 0 V 1 ENZALUTAMIDE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE193351 ruxolitinib 1 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE216273 GSE216292 palbociclib 14 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE173116 GSE173118 ML-7 3 v 5 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE216273,GSE216292 14 V 1 PALBOCICLIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE173483 nutlin-3 U2OS 1 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE172458 0 V 1 CISPLATIN HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE155031 5 V 3 DEXTRAN HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE193177 1 V 0 ST266 MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE217441,GSE217443 1 V 0 IVOSIDENIB MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.